Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 2/20 | 0.44 |
| ▸ | KDR | P35968 | 2/20 | 0.43 |
| ▸ | FLT1 | P17948 | 1/20 | 0.43 |
| ▸ | KDM1A | O60341 | 4/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.40 |
| ▸ | BCR | P11274 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4912881 | 0.94 | KDM1A (0.42) | ABL1KDRFLT1KDM1AEGFR | |
| SCHEMBL4910138 | 0.93 | ABL1 (0.44) | ABL1KDM1AEGFRERBB2BCR | |
| SCHEMBL4914057 | 0.92 | ABL1 (0.45) | ABL1KDRFLT1KDM1AEGFR | |
| SCHEMBL4911396 | 0.91 | ABL1 (0.41) | ABL1KDRFLT1KDM1AEGFR | |
| SCHEMBL4909827 | 0.91 | KDM1A (0.51) | ABL1KDM1AEGFRERBB2BCR | |
| SCHEMBL4912138 | 0.88 | ABL1 (0.43) | ABL1KDR | |
| SCHEMBL4907445 | 0.88 | EGFR (0.44) | KDRFLT1KDM1AEGFRERBB2 | |
| SCHEMBL4912634 | 0.88 | FLT1 (0.45) | KDRFLT1KDM1AEGFRERBB2 | |
| SCHEMBL4913007 | 0.87 | KDM1A (0.52) | ABL1KDM1A | |
| SCHEMBL4911309 | 0.87 | KDM1A (0.44) | ABL1KDM1AMEN1NPC1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8222297-B2 | e.g. 1-[3-(acridin-9-ylamino)-5-hydroxymethylphenyl]-3-{4-[bis(2-chloroethyl)amino]phenyl}urea; anticarcinogenic agent; improved chemical stability and efficacy; brain tumor, breast cancer, colon cancer, leukemia, and neuroblastoma | ACADEMIA SINICA (TW) | 2012-07-17 | — | — | US | disclosed |
| US-20080171765-A1 | Aniline or phenol mustards linked to DNA-affinic molecules or water-soluble aromatic rings and their use as cancer therapeutic agents | ACADEMIA SINICA (TW) | 2008-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171765-A1 | Aniline or phenol mustards linked to DNA-affinic molecules or water-soluble aromatic rings and their use as cancer therapeutic agents | WEE1, PCNA, ATIC | ABL1 679/4885KDR 1922/4885FLT1 2294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.